Oliver Surriga

Medicine · Health Sciences

8h-index457citations76works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ocular Oncology and Treatments(37), Cancer Mechanisms and Therapy(15), Retinal Development and Disorders(13), melanin and skin pigmentation(13), Nanoplatforms for cancer theranostics(12)

Publications76 total

Table S2 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S1 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Supplementary Data from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S4 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S2 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Data from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S1 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Supplementary Figure 5 from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Data from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Supplementary Figure 1 from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Supplementary Figure 4 from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Supplementary Figure 3 from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Supplementary Figure 3 from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Data from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Supplementary Figure 1 from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Supplementary Figure 2 from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Supplementary Figure Legend from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
Supplementary Figure Legend from Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Gary K. Schwartz(39), Grazia Ambrosini(22), Elisa de Stanchina(15), Parag P. Patwardhan(14), Michael J. Beckman(14), Ronald P. DeMatteo(14), William D. Tap(14), Richard D. Carvajal(10), John O. DaSilva(10), Katie Yang(8), Thomas Nittoli(8), Arthur Kunz(8), Matthew C. Franklin(8), Frank J. Delfino(8), Shu Mao(8), Feng Zhao(8), Jason T. Giurleo(8), Marcus P. Kelly(8), Sosina Makonnen(8), Carlos Hickey(8)